Figure 1From: Cost-effectiveness analysis of pneumococcal conjugate vaccine 13-valent in older adults in Colombia Markov microsimulation model of pneumococcal diseases to determine the cost-effectiveness of vaccination with PCV13, PPSV23 or not vaccine, in people older than 50 years in Colombia. Back to article page